The Expression Level of RAGE Forms in Different Cancer Cell Lines

Abstract

The receptor for advanced glycation end products (RAGE) is a cell surface multiligand receptor of the immunoglobulin superfamily. The interest of the researchers to RAGE was enhanced by the fact that it is expressed at low levels under normal physiology, but is upregulated in various pathological processes such as neuronal development, diabetes, inflammation, neurodegenerative disorders, cancer progression, cardiovascular disease (CVD), etc. The receptor can exist as full-length membrane bound and soluble form and it is considered that the balance between the amount of soluble and full-length RAGE might be a key factor for RAGE induced dysfunction. Different human cancer cell lines with various invasive potential were studied for the expression level of RAGE forms. Our finding shows that in less invasive cancers with better prognosis as MCF7 breast cancer and A549 (NSCLC – non small cell lung cancer) the membrane form of RAGE is the minor one and in A549 is even absent. Cancerous cells with great invasive potential and bad prognosis as MDA-MB-231, H1299 and HeLA expressed predominantly full-length receptor and sRAGE is poorly represented.